Key facts
- Notable investors include Alexandria Venture Investments, Perceptive Advisors, venBio, MRL Ventures Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Myoventive
- ·The full record, as it builds
Funding rounds
No funding rounds for Myoventive are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Myoventive
Provider of next-generation, non-viral RNA-based medicines intended for the treatment of genetic cardiac diseases. The company's targeted RNA modulation in the heart addresses genetic cardiac diseases that existing AAV platforms are unable to treat, enabling clients to access potentially safer, more scalable, and re-dosable genetic therapies.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2025
- Website
- myoventive.com/
- Ownership
- Privately Held (backing)
Myoventive doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Myoventive shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Myoventive in its N-PORT filings yet. We sweep new filings monthly.